8-K: Tourmaline Bio Announces Positive Phase 2 TRANQUILITY Trial Results for Pacibekitug in Patients with Elevated hs-CRP and Chronic Kidney Disease

Tourmaline Bio reports positive topline results from its Phase 2 TRANQUILITY trial, demonstrating significant hs-CRP reductions with pacibekitug in patients with elevated hs-CRP and chronic kidney disease, supporting further development in cardiovascular diseases.

Summary

• Tourmaline Bio announced positive topline results from its Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein (hs-CRP) and chronic kidney disease (CKD).
• The trial, a multicenter, randomized, double-blind, placebo-controlled study, involved patients with elevated hs-CRP and CKD stage 3 or 4.
• Participants received pacibekitug at 25 mg quarterly, 50 mg quarterly, or 15 mg monthly, or placebo, for six months, followed by a six-month observation period.
• The primary endpoint was the median time-averaged percent change in hs-CRP through Day 90, adjusted for baseline hs-CRP levels.
• Key secondary endpoints included the percentage of participants achieving time-averaged hs-CRP below 2 mg/L through Day 90.
• The primary analysis population consisted of 126 participants with a baseline hs-CRP of at least 1.9 mg/L.
• All pacibekitug arms achieved rapid, deep, and durable reductions in hs-CRP with high statistical significance compared to placebo (p<0.0001).
• The 50 mg quarterly arm achieved >85% hs-CRP reductions from baseline.
• Adverse event rates were comparable between pacibekitug and placebo groups.
• Tourmaline plans to advance pacibekitug into a potential Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease (ASCVD) and a Phase 2 proof-of-concept trial in abdominal aortic aneurysm (AAA) in the second half of 2025.

Sentiment

Score: 9

Explanation: The document presents highly positive results from a Phase 2 trial, with strong statistical significance and a favorable safety profile. The management's comments are enthusiastic, and the company is moving forward with Phase 3 planning. This suggests a very positive outlook for the company and its lead asset.

Positives

• Pacibekitug demonstrated rapid, deep, and durable reductions in hs-CRP across all dosing arms.
• The 50 mg quarterly arm achieved >85% hs-CRP reductions from baseline, showcasing the potential for less frequent dosing.
• Adverse event rates were comparable between pacibekitug and placebo groups, indicating a favorable safety profile.
• The results support the advancement of pacibekitug into Phase 3 trials for cardiovascular outcomes and a Phase 2 trial for abdominal aortic aneurysm.
• Pacibekitug is the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial.

Negatives

• One death occurred in the 25 mg quarterly arm due to a fatal case of COVID-19.
• The analysis is preliminary and reflects a data extract date of April 23, 2025, meaning the findings are subject to change as additional data are collected.
• The study population included patients with CKD stage 3 or 4, which may limit the generalizability of the results to other populations.

Risks

• The forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• Additional safety events could occur as participants complete their trial visits and follow-up.
• A review of the full dataset after trial completion may cause the analysis to differ from the analysis as of the data extract date.
• Unexpected safety or efficacy data could be observed during preclinical or clinical studies.
• Clinical site activation or trial enrollment rates could be lower than expected.
• Changes in the regulatory environment or increased competition could impact the development and commercialization of pacibekitug.

Future Outlook

Tourmaline Bio plans to advance the clinical development of pacibekitug, including a potential Phase 3 cardiovascular outcomes trial in ASCVD and a Phase 2 proof-of-concept trial in AAA. The company expects to provide further updates on these plans later in 2025.

Management Comments

• Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline, stated that they are thrilled with the data emerging from the TRANQUILITY trial and the remarkable consistency of signal across all endpoints evaluated.
• Sandeep Kulkarni noted that this is the first time that pacibekitug or any IL-6 inhibitor has been tested in a clinical trial with quarterly dosing, which has the potential to enhance patient adherence and ultimate clinical benefit.
• Dr. Deepak L. Bhatt stated that pacibekitug merits testing in future Phase 3 trials for cardiovascular risk reduction.

Industry Context

The announcement highlights the increasing focus on IL-6 inhibition as a potential therapeutic strategy for cardiovascular diseases. Several other companies are also developing IL-6 inhibitors for various indications, including cardiovascular disease, making this a competitive area of research.

Comparison to Industry Standards

• Ziltivekimab, another IL-6 inhibitor, is being developed for cardiovascular risk reduction in patients with chronic kidney disease and elevated hs-CRP.
• Unlike ziltivekimab, which is administered monthly, pacibekitug has shown potential for quarterly dosing, which could offer a more convenient treatment option for patients.
• Clazakizumab is another IL-6 inhibitor being investigated for cardiovascular indications, but it has a different route of administration (IV) and dosing schedule (monthly) compared to pacibekitug.
• The CANTOS trial with canakinumab (an anti-IL-1β antibody) demonstrated the potential of targeting inflammation to reduce cardiovascular events, providing a precedent for the development of anti-inflammatory therapies like pacibekitug.

Stakeholder Impact

• Shareholders: The positive trial results are likely to be viewed favorably by shareholders, potentially increasing the company's stock price.
• Patients: If pacibekitug is ultimately approved, it could provide a new treatment option for patients with cardiovascular disease and chronic kidney disease.
• Employees: The advancement of pacibekitug could create new job opportunities within the company.
• Suppliers: Increased demand for pacibekitug could benefit the company's suppliers.

Next Steps

• Tourmaline will consult with its Cardiovascular Scientific Advisory Board to confirm the optimal dose for a Phase 3 cardiovascular outcomes trial in ASCVD and finalize the clinical development strategy.
• The company plans to conduct an end-of-Phase 2 meeting with the FDA by the end of the year.
• Tourmaline intends to initiate a Phase 2 proof-of-concept trial in patients with abdominal aortic aneurysm (AAA) in the second half of 2025.

Key Dates

Keywords

pacibekitug, hs-CRP, TRANQUILITY trial, cardiovascular disease, chronic kidney disease, IL-6 inhibitor, atherosclerotic cardiovascular disease, abdominal aortic aneurysm, clinical trial, Tourmaline Bio